Posts Tagged ‘orforglipron’

In Lancet yesterday, Julio Rosenstock and colleagues published the results of a head-to-head comparison of orforglipron versus oral semaglutide in adults with type 2 diabetes and a BMI greater than 25. Headlines would have you believe this was a clear win for orforglipron over semaglutide. But it’s not quite that simple. The Study Details The […]

The slate is clean. All is forgiven. We have a fresh new year ahead. So that has us thinking about the trends that are likely to define 2026 in obesity, nutrition, and health. Here are five that floated to the top of our mind. 1. Healthy Weight for Life We have said it before. Weight […]

We strongly suspect that advanced oral obesity medicines may be a defining milestone for 2026. This is because they have the potential to fill an important gap in obesity therapy – the unmet need for therapies that people can persistently take to maintain control of this chronic disease. Late yesterday, FDA granted approval for the […]

News from Lilly about orforglipron this week points to what might be the next big development for GLP-1 medicines. The company announced topline results for a weight maintenance study of orforglipron and this first glimpse has us thinking that maintain might be the magic word in obesity care next year. The topline come from the […]

The sprint to the finish for orforglipron is picking up pace with a pivotal trial in obesity and diabetes published yesterday in The Lancet. Things are looking good for this relatively simple GLP-1 agonist in a tablet. The presentation of these results from ATTAIN-2 were a highlight of ObesityWeek earlier this month, but having this […]

This is a perilous and exciting time for investing in obesity innovation as the market for treating this disease advances dramatically. On the side of excitement, we note that the David Wainer in the Wall Street Journal predicts that “obesity drugs are about to go mass market.” Perilous for Novo On the side of peril, […]

This has been quite a week and the ideas we take home from ObesityWeek 2025 come from both inside and outside of the event in Atlanta. It is a reflection of the fact that the work of cloistered insiders in obesity is and will continue to have large effects in the larger world outside of […]

President Trump held a press event yesterday to issue some very welcome news on coverage and prices for obesity medicines. On prices, they are coming down. In reality, this is an extension of the ongoing trend of downward pressure on these prices that has been in play since the day that semaglutide and tirzepatide launched […]

At ObesityWeek in Atlanta, people are speculating about innovations that health professionals in general practice can embrace widely. We’re getting a good look at two candidates to become the GP GLP-1. Providing real obesity care and prescribing these medicines for more than a small portion of patients who need them is far from the norm. […]

We’re packing our bags and scanning the meeting app for ObesityWeek in Atlanta, November 4-7. This promises to be a very intense week, with the biggest attendance yet for this signature meeting of the Obesity Society. The agenda for the week has a lot of options and we are still processing them all. But for […]